GlassScriptPhysician profile
Kenneth J Vito
NPI 1629048194
$8,001.00
in general payments reported to CMS, 2019-2025
14 companies · $983 in 2025
The $983 reported for 2025 was more than what 79% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,619 · 2020: $209 · 2021: $209 · 2022: $2,572 · 2023: $635 · 2024: $776 · 2025: $983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,393.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $5,317.38 | 2019-2025 | Inspire |
| Stryker Corporation | $1,655.41 | 2019-2024 | Scopis Ent |
| Optinose US, INC. | $387.90 | 2019-2025 | |
| Glaxosmithkline, LLC. | $306.78 | 2021-2025 | Nucala |
| Karl Storz Endoscopy-America | $109.89 | 2022 | |
| Medtronic, INC. | $62.06 | 2024-2025 | Propel, Ligasure |
| Acclarent, INC | $37.75 | 2019 | |
| Genzyme Corporation | $34.70 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $21.13 | 2025 | Tezspire |
| Cochlear Americas | $18.27 | 2023 | Osia Osi300 Implant, Baha, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode |
| Paratek Pharmaceuticals, INC. | $15.40 | 2025 | Xhance |
| Philips North America LLC | $15.37 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $14.56 | 2019 | |
| Ambu INC. | $4.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Vito listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.